EcoDrugPlus

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSPMAG00000007396
Gene Symbol: CHRM3
1 Cross references
256 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSPMAG00000007576
Gene Symbol: CHRNA3
1 Cross references
207 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5a

Ensembl ID : ENSPMAG00000000621
Gene Symbol: CHRM5A
1 Cross references
282 Possible Orthologues:

Coagulation Factor Ii (Thrombin) Receptor-Like 1, Tandem Duplicate 1

Ensembl ID : ENSPMAG00000002211
Gene Symbol: F2RL1.1
1 Cross references
1097 Possible Orthologues:

Coiled-Coil Domain Containing 6b

Ensembl ID : ENSPMAG00000003012
Gene Symbol: CCDC6B
1 Cross references
219 Possible Orthologues:

Cyclin Dependent Kinase 9

Ensembl ID : ENSPMAG00000006237
Gene Symbol: CDK9
1 Cross references
206 Possible Orthologues:

Cyclin-Dependent Kinase 1

Ensembl ID : ENSPMAG00000005117
Gene Symbol: CDK1
1 Cross references
246 Possible Orthologues:

Cyclin-Dependent Kinase 2

Ensembl ID : ENSPMAG00000003902
Gene Symbol: CDK2
1 Cross references
202 Possible Orthologues:

Cyclin-Dependent Kinase 2

Ensembl ID : ENSPMAG00000003251
Gene Symbol: CDK2
1 Cross references
202 Possible Orthologues:

Cyclin-Dependent Kinase 4

Ensembl ID : ENSPMAG00000002743
Gene Symbol: CDK4
1 Cross references
240 Possible Orthologues:

Cyclin-Dependent Kinase 7

Ensembl ID : ENSPMAG00000001064
Gene Symbol: CDK7
1 Cross references
218 Possible Orthologues:

Cysteinyl Leukotriene Receptor 1

Ensembl ID : ENSPMAG00000010426
Gene Symbol: CYSLTR1
1 Cross references
244 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).